已收盤 11-20 16:00:00 美东时间
-0.640
-2.35%
Ionis Pharmaceuticals has seen its share price slide sharply in 2026, which puts fresh attention on whether the current valuation is still in line with what its sales can support. With sentiment now heavily influenced by product launches, revised expectations and headline risk, the central issue is how much revenue the business needs to justify where the stock trades today. The share price is down 66.6% year to date, so the question for you is wh
今天 00:09
11月20日,Ionis Pharmaceuticals Inc(IONS)收跌0.62%,报27.22美元,成交额8301.04万美元,市值45.33亿美元...
11-20 06:09
今日重点评级关注:HC Wainwright & Co.:维持Cerenome"买入"评级,目标价从1美元升至7美元;HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从69美元升至70美元
11-19 19:40
Biogen Inc. (NASDAQ:BIIB) announced Tuesday that its investigational therapy diranersen slowed clinical decline at two years in people living with early Alzheimer’s disease, according to new Phase 2 CELIA study data. Presenters shared the Week 96 findings at the Clinical Trials on Alzheimer’s Diseas...
11-18 23:40
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $80 to $65.
11-18 21:51
渤健(BIIB.US)的 diranersen 用于早期阿尔茨海默病的 2 期开放标签延展数据显示,该在研药在两年内使临床衰退显著放缓。 按 60 毫克、每半年...
11-18 10:15
Biogen's Phase 2 CELIA study shows that diranersen, an investigational antisense oligonucleotide targeting tau, slowed clinical decline in early Alzheimer's disease. At two years (Week 96), the 60 mg twice-yearly regimen reduced clinical decline by 38% on the CDR-SB scale, with benefits observed across all doses. The study, presented at the CTAD conference, highlights diranersen's potential to slow disease progression, improve cognitive and funct...
11-17 21:45
11月14日,Ionis Pharmaceuticals Inc(IONS)收涨6.41%,报29.06美元,成交额1.69亿美元,市值48.4亿美元。 行情数...
11-14 06:07
今日重点评级关注:花旗:维持Faeth Therapeutics"买入"评级,目标价从55美元升至60美元;HC Wainwright & Co.:维持Ocular Therapeutix"买入"评级,目标价从25美元升至28美元
11-11 10:50
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $95 to $80.
11-10 23:12